» Articles » PMID: 31351234

The Glucose-6-phosphate Dehydrogenase Mahidol Variant Protects Against Uncomplicated Plasmodium Vivax Infection and Reduces Disease Severity in a Kachin Population from Northeast Myanmar

Overview
Date 2019 Jul 28
PMID 31351234
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common red cell disorders in the world. The aim of this study was to investigate whether the G6PD Mahidol variant and haplotype 1311 T/93C, which are prevalent in the Kachin ethnic population along the China-Myanmar border area, offer protection against Plasmodium vivax infection. Malaria was monitored in nine villages near the Laiza township, Kachin State, Myanmar, where 258 cases of uncomplicated P. vivax were identified in 2013-2017. From the same villages, 250 unrelated, malaria-free participants were recruited to serve as the control cohort. Quantitative enzyme activity analysis in 100 healthy individuals identified that both male hemizygotes and female heterozygotes of the G6PD Mahidol variant had on average ~40% lower enzyme activity relative to the wild-type individuals. Compared with the overall prevalence of 25.2% in the control cohort, the G6PD Mahidol variant had a significantly lower prevalence (7.0%) among the 258 vivax patients (P <  .0001, χ test). Logistic regression analysis of G6PD genotypes stratified by sex showed that the individuals with the Mahidol 487A allele had dramatically reduced odds of having acute vivax malaria (adjusted odds ratio = 0.213 for male 487A hemizygotes, P < .0001, and 0.248 for female 487GA heterozygotes, P < .001). Furthermore, both 487A hemizygous male and 487GA heterozygous female patients had significantly lower asexual parasitemias than the wild-type patients, suggesting a potential effect on alleviating disease severity. In contrast, the silent mutation haplotype 1311 T/93C was highly prevalent (49.6%) in the study population, but it was not associated with altered G6PD enzymatic activities nor did it seem to provide protection against vivax infection or disease severity. Taken together, this study provided evidence that the Mahidol G > A mutation offers protection against P. vivax infection and potentially reduces disease severity in a Kachin population.

Citing Articles

Exploiting integrative metabolomics to study host-parasite interactions in Plasmodium infections.

Nikulkova M, Abdrabou W, Carlton J, Idaghdour Y Trends Parasitol. 2024; 40(4):313-323.

PMID: 38508901 PMC: 10994734. DOI: 10.1016/j.pt.2024.02.007.


Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.

Taylor W, Meagher N, Ley B, Thriemer K, Bancone G, Satyagraha A PLoS Negl Trop Dis. 2023; 17(9):e0011522.

PMID: 37672548 PMC: 10482257. DOI: 10.1371/journal.pntd.0011522.


Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya.

Olewe P, Awandu S, Munde E, Anyona S, Raballah E, Amolo A BMC Cancer. 2023; 23(1):566.

PMID: 37340364 PMC: 10280846. DOI: 10.1186/s12885-023-11063-2.


Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.

Aung P, Soe M, Soe T, Oo T, Win K, Cui L Sci Rep. 2023; 13(1):5963.

PMID: 37045879 PMC: 10091336. DOI: 10.1038/s41598-023-32371-4.


Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.

Nain M, Gill J, Mohan M, Sharma A Am J Trop Med Hyg. 2023; 108(3):470-476.

PMID: 36746659 PMC: 9978548. DOI: 10.4269/ajtmh.22-0468.


References
1.
Chu C, Freedman D . Tafenoquine and G6PD: a primer for clinicians. J Travel Med. 2019; 26(4). PMC: 6542331. DOI: 10.1093/jtm/taz023. View

2.
Luzzatto L, Seneca E . G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2013; 164(4):469-80. PMC: 4153881. DOI: 10.1111/bjh.12665. View

3.
Manjurano A, Sepulveda N, Nadjm B, Mtove G, Wangai H, Maxwell C . African glucose-6-phosphate dehydrogenase alleles associated with protection from severe malaria in heterozygous females in Tanzania. PLoS Genet. 2015; 11(2):e1004960. PMC: 4335500. DOI: 10.1371/journal.pgen.1004960. View

4.
Moiz B, Nasir A, Moatter T, Naqvi Z, Khurshid M . Population study of 1311 C/T polymorphism of Glucose 6 Phosphate Dehydrogenase gene in Pakistan - an analysis of 715 X-chromosomes. BMC Genet. 2009; 10:41. PMC: 2725355. DOI: 10.1186/1471-2156-10-41. View

5.
Nuchprayoon I, Louicharoen C, Charoenvej W . Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. J Hum Genet. 2007; 53(1):48-54. DOI: 10.1007/s10038-007-0217-3. View